Lazard Asset Management
ENTA icon

Lazard Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Lazard Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,145
Closed -$65K – 2328
2021
Q3 		$65K Buy
+1,145
New +$56.6K ﹤0.01% 1565
2020
Q4 		– Sell
-985
Closed -$45K – 1875
2020
Q3 		$45K Sell
985
-201
-17% -$9.74K ﹤0.01% 1217
2020
Q2 		$59K Buy
1,186
+176
+17% +$9.11K ﹤0.01% 1184
2020
Q1 		$51K Buy
1,010
+260
+35% +$13.9K ﹤0.01% 1164
2019
Q4 		$46K Buy
750
+569
+314% +$35.3K ﹤0.01% 1076
2019
Q3 		$10K Buy
+181
New +$13.4K ﹤0.01% 1304
2018
Q2 		– Sell
-19,058
Closed -$1.54M – 1049
2018
Q1 		$1.54M Buy
19,058
+6,990
+58% +$538K ﹤0.01% 672
2017
Q4 		$708K Buy
+12,068
New +$604K ﹤0.01% 731
2015
Q1 		– Sell
-93,715
Closed -$4.76M – 1144
2014
Q4 		$4.76M Buy
93,715
+88,120
+1,575% +$3.95M 0.01% 548
2014
Q3 		$221K Buy
+5,595
New +$223K ﹤0.01% 827

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Lazard Asset Management's ENTA Position: Q4 2021 in Review

Lazard Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2021, closing a stake of 1,145 shares — an estimated $65K sold.

Lazard Asset Management first reported a position in ENTA in Q3 2014 and held it in 10 quarters. The position peaked at $4.76M in Q4 2014. 179 funds tracked by Wall St. Rank hold ENTA as of Q4 2021.

  • Lazard Asset Management reported no remaining Enanta Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Lazard Asset Management sold 1,145 Enanta Pharmaceuticals shares in Q4 2021, an estimated $65K.
  • Lazard Asset Management first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 10 quarters.
  • Lazard Asset Management's Enanta Pharmaceuticals position peaked at $4.76M in Q4 2014.
  • 179 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2021.

Based on Lazard Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.